Drug Profile
Camptothecin/fleximer conjugate
Alternative Names: MER-1001; XMT-1001Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Mersana Therapeutics
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
- 14 May 2018 Mersana Therapeutics has patent protection for its Fleximer polymer-based Dolaflexin platform in USA
- 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union